Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 204

1.

Role of Host GPR120 in Mediating Dietary Omega-3 Fatty Acid Inhibition of Prostate Cancer.

Liang P, Henning SM, Guan J, Grogan T, Elashoff D, Olefsky JM, Cohen P, Aronson WJ.

J Natl Cancer Inst. 2018 Sep 6. doi: 10.1093/jnci/djy125. [Epub ahead of print]

PMID:
30202902
2.

Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study.

Sandler KA, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Song DY, Klein EA, Stephenson AJ, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco SC, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR, Kishan AU.

Int J Radiat Oncol Biol Phys. 2018 Jul 15;101(4):883-888. doi: 10.1016/j.ijrobp.2018.03.060. Epub 2018 Apr 5.

PMID:
29976500
3.

Is Ki67 prognostic for aggressive prostate cancer? A multicenter real-world study.

Fantony JJ, Howard LE, Csizmadi I, Armstrong AJ, Lark AL, Galet C, Aronson WJ, Freedland SJ.

Biomark Med. 2018 Jul;12(7):727-736. doi: 10.2217/bmm-2017-0322. Epub 2018 Jun 15.

PMID:
29902938
4.

Reply to the letter by Demark-Wahnefried et al.

Aronson WJ, Henning SM.

Prostate Cancer Prostatic Dis. 2018 Jun;21(2):295. doi: 10.1038/s41391-018-0050-0. Epub 2018 Jun 1. No abstract available.

PMID:
29858594
5.

Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH database.

Vidal AC, Howard LE, de Hoedt A, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, Amling CL, Taioli E, Fowke JH, Freedland SJ.

Cancer Causes Control. 2018 Jun;29(6):581-588. doi: 10.1007/s10552-018-1031-2. Epub 2018 Apr 17.

PMID:
29663110
6.

Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.

Vidal AC, Howard LE, de Hoedt A, Kane CJ, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Freedland SJ.

BJU Int. 2018 Jul;122(1):76-82. doi: 10.1111/bju.14193. Epub 2018 Apr 10.

PMID:
29521009
7.

Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.

Kishan AU, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Sandler KA, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Stephenson AJ, Klein EA, Song DY, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco S, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR.

JAMA. 2018 Mar 6;319(9):896-905. doi: 10.1001/jama.2018.0587.

8.

Radical prostatectomy and the effect of close surgical margins: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.

Herforth C, Stroup SP, Chen Z, Howard LE, Freedland SJ, Moreira DM, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Kane CJ.

BJU Int. 2018 Feb 23. doi: 10.1111/bju.14178. [Epub ahead of print]

PMID:
29473992
9.

First postoperative PSA is associated with outcomes in patients with node positive prostate cancer: Results from the SEARCH database.

McDonald ML, Howard LE, Aronson WJ, Terris MK, Cooperberg MR, Amling CL, Freedland SJ, Kane CJ.

Urol Oncol. 2018 May;36(5):239.e17-239.e25. doi: 10.1016/j.urolonc.2018.01.005. Epub 2018 Feb 9.

PMID:
29429895
10.

Phase II prospective randomized trial of weight loss prior to radical prostatectomy.

Henning SM, Galet C, Gollapudi K, Byrd JB, Liang P, Li Z, Grogan T, Elashoff D, Magyar CE, Said J, Cohen P, Aronson WJ.

Prostate Cancer Prostatic Dis. 2018 Jun;21(2):212-220. doi: 10.1038/s41391-017-0001-1. Epub 2017 Dec 4.

11.

Modified risk stratification grouping using standard clinical and biopsy information for patients undergoing radical prostatectomy: Results from SEARCH.

Zumsteg ZS, Chen Z, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Spratt DE, Sandler HM, Freedland SJ.

Prostate. 2017 Dec;77(16):1592-1600. doi: 10.1002/pros.23436. Epub 2017 Oct 10.

PMID:
28994485
12.

Does Early Prostate Specific Antigen Doubling Time after Radical Prostatectomy, Calculated Prior to Prostate Specific Antigen Recurrence, Correlate with Prostate Cancer Outcomes? A Report from the SEARCH Database Group.

Teeter AE, Griffin K, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ.

J Urol. 2018 Mar;199(3):713-718. doi: 10.1016/j.juro.2017.08.107. Epub 2017 Sep 1.

PMID:
28870860
13.

In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database.

Whitney CA, Howard LE, Posadas EM, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ.

Eur Urol Focus. 2017 Oct;3(4-5):480-486. doi: 10.1016/j.euf.2016.08.007. Epub 2016 Aug 29.

PMID:
28753787
14.

Timing of Prostate-specific Antigen Nadir After Radical Prostatectomy and Risk of Biochemical Recurrence.

Skove SL, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Moreira DM, Freedland SJ.

Urology. 2017 Oct;108:129-134. doi: 10.1016/j.urology.2017.07.009. Epub 2017 Jul 19.

PMID:
28735016
15.

Biopsy Detected Gleason Pattern 5 is Associated with Recurrence, Metastasis and Mortality in a Cohort of Men with High Risk Prostate Cancer.

Stroup SP, Moreira DM, Chen Z, Howard L, Berger JH, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Kane CJ, Freedland SJ.

J Urol. 2017 Dec;198(6):1309-1315. doi: 10.1016/j.juro.2017.07.009. Epub 2017 Jul 11.

PMID:
28709888
16.

Follow-up of Prostatectomy versus Observation for Early Prostate Cancer.

Wilt TJ, Jones KM, Barry MJ, Andriole GL, Culkin D, Wheeler T, Aronson WJ, Brawer MK.

N Engl J Med. 2017 Jul 13;377(2):132-142. doi: 10.1056/NEJMoa1615869.

17.

Predictors of operative time during radical retropubic prostatectomy and robot-assisted laparoscopic prostatectomy.

Simon RM, Howard LE, Moreira DM, Terris MK, Kane CJ, Aronson WJ, Amling CL, Cooperberg MR, Freedland SJ.

Int J Urol. 2017 Aug;24(8):618-623. doi: 10.1111/iju.13393. Epub 2017 Jul 11.

18.

Validation of the 2015 prostate cancer grade groups for predicting long-term oncologic outcomes in a shared equal-access health system.

Schulman AA, Howard LE, Tay KJ, Tsivian E, Sze C, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ, Polascik TJ.

Cancer. 2017 Nov 1;123(21):4122-4129. doi: 10.1002/cncr.30844. Epub 2017 Jun 29.

PMID:
28662291
19.

Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database.

Freedland SJ, Vidal AC, Howard LE, Terris MK, Cooperberg MR, Amling CL, Kane CJ, Aronson WJ; Shared Equal Access Regional Cancer Hospital (SEARCH) Database Study Group.

Cancer. 2017 Nov 1;123(21):4199-4206. doi: 10.1002/cncr.30834. Epub 2017 Jun 27.

PMID:
28654204
22.

Characterization of a "low-risk" cohort of grade group 2 prostate cancer patients: Results from the Shared Equal Access Regional Cancer Hospital database.

McGinley KF, Sun X, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ.

Int J Urol. 2017 Aug;24(8):611-617. doi: 10.1111/iju.13387. Epub 2017 Jun 6.

23.

Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer.

Howard LE, Moreira DM, De Hoedt A, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ.

BJU Int. 2017 Nov;120(5B):E80-E86. doi: 10.1111/bju.13856. Epub 2017 Apr 30.

PMID:
28371163
24.

Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer.

Klaassen Z, Howard LE, de Hoedt A, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ.

Cancer. 2017 May 1;123(9):1528-1535. doi: 10.1002/cncr.30505. Epub 2016 Dec 27.

25.

Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy.

Leapman MS, Freedland SJ, Aronson WJ, Kane CJ, Terris MK, Walker K, Amling CL, Carroll PR, Cooperberg MR.

J Urol. 2016 Nov;196(5):1408-1414. doi: 10.1016/j.juro.2016.06.086. Epub 2016 Jun 25.

26.

Keratin 13 Is Enriched in Prostate Tubule-Initiating Cells and May Identify Primary Prostate Tumors that Metastasize to the Bone.

Liu S, Cadaneanu RM, Zhang B, Huo L, Lai K, Li X, Galet C, Grogan TR, Elashoff D, Freedland SJ, Rettig M, Aronson WJ, Knudsen BS, Lewis MS, Garraway IP.

PLoS One. 2016 Oct 6;11(10):e0163232. doi: 10.1371/journal.pone.0163232. eCollection 2016.

27.

Long-term oncological outcomes of apical positive surgical margins at radical prostatectomy in the Shared Equal Access Regional Cancer Hospital cohort.

Wadhwa H, Terris MK, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ, Abern MR.

Prostate Cancer Prostatic Dis. 2016 Dec;19(4):423-428. doi: 10.1038/pcan.2016.45. Epub 2016 Oct 4.

PMID:
27698440
28.

Obesity and prostate cancer-specific mortality after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.

Vidal AC, Howard LE, Sun SX, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, Amling CL, Freedland SJ.

Prostate Cancer Prostatic Dis. 2017 Mar;20(1):72-78. doi: 10.1038/pcan.2016.47. Epub 2016 Oct 4.

29.

Predicting Time From Metastasis to Overall Survival in Castration-Resistant Prostate Cancer: Results From SEARCH.

Moreira DM, Howard LE, Sourbeer KN, Amarasekara HS, Chow LC, Cockrell DC, Pratson CL, Hanyok BT, Aronson WJ, Kane CJ, Terris MK, Amling CL, Cooperberg MR, Freedland SJ.

Clin Genitourin Cancer. 2017 Feb;15(1):60-66.e2. doi: 10.1016/j.clgc.2016.08.018. Epub 2016 Aug 31.

30.

Number of Unfavorable Intermediate-Risk Factors Predicts Pathologic Upstaging and Prostate Cancer-Specific Mortality Following Radical Prostatectomy: Results From the SEARCH Database.

Zumsteg ZS, Chen Z, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Spratt DE, Sandler HM, Freedland SJ.

Prostate. 2017 Feb;77(2):154-163. doi: 10.1002/pros.23255. Epub 2016 Sep 29.

PMID:
27683213
31.

Race does not predict the development of metastases in men with nonmetastatic castration-resistant prostate cancer.

Whitney CA, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ.

Cancer. 2016 Dec 15;122(24):3848-3855. doi: 10.1002/cncr.30221. Epub 2016 Aug 9.

32.

Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis.

Kishan AU, Shaikh T, Wang PC, Reiter RE, Said J, Raghavan G, Nickols NG, Aronson WJ, Sadeghi A, Kamrava M, Demanes DJ, Steinberg ML, Horwitz EM, Kupelian PA, King CR.

Eur Urol. 2017 May;71(5):766-773. doi: 10.1016/j.eururo.2016.06.046. Epub 2016 Jul 21.

PMID:
27452951
33.

Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer?

Howard LE, De Hoedt AM, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Divers CH, Valderrama A, Freedland SJ.

Prostate Cancer Prostatic Dis. 2016 Dec;19(4):380-384. doi: 10.1038/pcan.2016.26. Epub 2016 Jul 5.

34.

Effect of Dietary Omega-3 Fatty Acids on Tumor-Associated Macrophages and Prostate Cancer Progression.

Liang P, Henning SM, Schokrpur S, Wu L, Doan N, Said J, Grogan T, Elashoff D, Cohen P, Aronson WJ.

Prostate. 2016 Oct;76(14):1293-302. doi: 10.1002/pros.23218. Epub 2016 Jun 24.

35.

Predictors of Time to Metastasis in Castration-resistant Prostate Cancer.

Moreira DM, Howard LE, Sourbeer KN, Amarasekara HS, Chow LC, Cockrell DC, Hanyok BT, Aronson WJ, Kane CJ, Terris MK, Amling CL, Cooperberg MR, Liede A, Freedland SJ.

Urology. 2016 Oct;96:171-176. doi: 10.1016/j.urology.2016.06.011. Epub 2016 Jun 16. Erratum in: Urology. 2017 May;103:280-281.

36.

Variations in payment patterns for surgical care in the centers for Medicare and Medicaid Services.

Bergman J, Laviana AA, Kwan L, Lerman SE, Aronson WJ, Bennett CJ, Hu JJ.

Surgery. 2017 Feb;161(2):312-319. doi: 10.1016/j.surg.2015.12.028. Epub 2016 Feb 26. Review.

PMID:
26922367
37.

Racial Differences in the Association Between Preoperative Serum Cholesterol and Prostate Cancer Recurrence: Results from the SEARCH Database.

Allott EH, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ.

Cancer Epidemiol Biomarkers Prev. 2016 Mar;25(3):547-54. doi: 10.1158/1055-9965.EPI-15-0876. Epub 2016 Jan 25.

38.

Validation of a bone scan positivity risk table in non-metastatic castration-resistant prostate cancer.

Freedland SJ, Howard LE, Hanyok BT, Kadiyala VK, Kuang JY, Whitney CA, Wilks FR, Kane CJ, Terris MK, Amling CL, Cooperberg MR, Aronson WJ, Moreira DM.

BJU Int. 2016 Oct;118(4):570-7. doi: 10.1111/bju.13405. Epub 2016 Feb 8.

39.

Utilization and impact of surgical technique on the performance of pelvic lymph node dissection at radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital database.

McGinley KF, Sun X, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ.

Int J Urol. 2016 Mar;23(3):241-6. doi: 10.1111/iju.13027. Epub 2015 Dec 14.

40.

Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database.

Hanyok BT, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Posadas EM, Freedland SJ.

Cancer. 2016 Jan 15;122(2):222-9. doi: 10.1002/cncr.29748. Epub 2015 Oct 20.

41.

Does larger tumor volume explain the higher prostate specific antigen levels in black men with prostate cancer--Results from the SEARCH database.

Klaassen Z, Howard L, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Kane CJ, Freedland SJ.

Cancer Epidemiol. 2015 Dec;39(6):1066-70. doi: 10.1016/j.canep.2015.09.007. Epub 2015 Oct 6.

42.

Do all men with pathological Gleason score 8-10 prostate cancer have poor outcomes? Results from the SEARCH database.

Fischer S, Lin D, Simon RM, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ, Vidal AC.

BJU Int. 2016 Aug;118(2):250-7. doi: 10.1111/bju.13319. Epub 2015 Oct 8.

43.

Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer.

Moreira DM, Howard LE, Sourbeer KN, Amarasekara HS, Chow LC, Cockrell DC, Hanyok BT, Pratson CL, Aronson WJ, Kane CJ, Terris MK, Amling CL, Cooperberg MR, Liede A, Freedland SJ.

Prostate Cancer Prostatic Dis. 2015 Dec;18(4):333-7. doi: 10.1038/pcan.2015.25. Epub 2015 May 26.

44.

Adverse pathology and undetectable ultrasensitive prostate-specific antigen after radical prostatectomy: is adjuvant radiation warranted?

Simon RM, Howard LE, Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Vidal AC.

BJU Int. 2016 Jun;117(6):897-903. doi: 10.1111/bju.13182. Epub 2015 Jun 23.

45.

Positive surgical margins in radical prostatectomy patients do not predict long-term oncological outcomes: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) cohort.

Mithal P, Howard LE, Aronson WJ, Terris MK, Cooperberg MR, Kane CJ, Amling C, Freedland SJ.

BJU Int. 2016 Feb;117(2):244-8. doi: 10.1111/bju.13181. Epub 2015 Jun 23.

46.

Agent Orange and long-term outcomes after radical prostatectomy.

Ovadia AE, Terris MK, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ, Abern MR.

Urol Oncol. 2015 Jul;33(7):329.e1-6. doi: 10.1016/j.urolonc.2015.04.012. Epub 2015 May 18.

47.

Smoking is a predictor of adverse pathological features at radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital database.

Zapata DF, Howard LE, Aronson WJ, Kane CJ, Terris MK, Amling CL, Cooperberg MR, Freedland SJ.

Int J Urol. 2015 Jul;22(7):658-62. doi: 10.1111/iju.12773. Epub 2015 Apr 14.

48.

Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.

Mithal P, Howard LE, Aronson WJ, Kane CJ, Cooperberg MR, Terris MK, Amling CL, Freedland SJ.

Int J Urol. 2015 Apr;22(4):362-6. doi: 10.1111/iju.12704. Epub 2015 Feb 24.

49.

Randomized clinical trial of brewed green and black tea in men with prostate cancer prior to prostatectomy.

Henning SM, Wang P, Said JW, Huang M, Grogan T, Elashoff D, Carpenter CL, Heber D, Aronson WJ.

Prostate. 2015 Apr 1;75(5):550-9. doi: 10.1002/pros.22943. Epub 2014 Dec 24.

50.

Is clinical stage T2c prostate cancer an intermediate- or high-risk disease?

Klaassen Z, Singh AA, Howard LE, Feng Z, Trock B, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Kane CJ, Partin A, Han M, Freedland SJ.

Cancer. 2015 May 1;121(9):1414-21. doi: 10.1002/cncr.29147. Epub 2014 Dec 9.

Supplemental Content

Loading ...
Support Center